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ABSTRACT
Emotion is a crucial component of the decision-making process. The
amygdala, known as the “orchestrator” of the emotion circuit, associates
emotional valence with incoming sensory stimuli and thus contributes to decisionmaking. Within the basolateral nucleus of the amygdala (BLA), spatially
segregated and genetically distinct pyramidal neurons (PNs) have been identified
based on their correspondence to distinct behavioral stimuli. These PNs project
to several brain regions mediating different aspects of the emotional spectrum.
For example, BLA PNs projecting to prelimbic (PL) and infralimbic (IL) cortex are
involved in fear acquisition and fear extinction, respectively. However, the
mechanism by which these distinct PNs are modulated and whether this
modulation differs depending on their projection targets remains unclear. The
BLA is densely innervated by cholinergic fibers from the basal forebrain, and the
contributions of acetylcholine (ACh) to selective attention, emotion, and other
cognitive functions suggest a modulatory role of this neurotransmitter in the BLA.
Here, we have used confocal immunofluorescence to examine the anatomical
distribution of cholinergic markers across the BLA relative to PNs, including those
projecting to PL and IL, to establish an anatomical basis for cholinergic
modulation of different PNs. Immunoreactivity for both postsynaptic M1
muscarinic receptors and vesicular ACh transporter (vAChT), a marker of
cholinergic terminals, was significantly greater in the dorsorostral region of the
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anterior BLA (BLAa) compared to other regions of the BLA or other amygdalar
subnuclei (n=6). M1R immunoreactivity was preferentially localized to
magnocellular PNs in the BLAa (n = 6). These magnocellular PNs have
previously been found to be responsive to stimuli of negative valence. In
contrast, parvocellular PNs, which are responsive to stimuli of positive valence,
were located in posterior BLA (BLAp), exhibited significantly less M1R
immunoreactivity and were associated with significantly less cholinergic
innervation. PNs projecting to PL (PL-projectors), which were prominently found
in BLAa, expressed higher M1 intensity than those projecting to IL, which were
more equally distributed between BLA subnuclei. Altogether, these data provide
an anatomical basis for preferential cholinergic modulation of negative valenceencoding PNs in the BLA.
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CHAPTER I: INTRODUCTION
A) Emotion and Decision-Making:
People make decisions every day. In his book The Paradox of Choice:
Why more is less, psychologist Barry Schwartz discussed the unfathomable
amount of choices that an average American has to face (Schwartz). We make
decisions from the moment we wake up until we go to bed at night. It seems that
we as a society are being impacted by facets of choices. Most people are
probably not able to remember the majority of the normal, mundane choices they
make every day. However, many can recall precisely the more impactful
decisions made during critical situations, such as swerving left or right during a
car accident. During those moments, people make seemingly instantaneous
decisions that they can almost always recall vividly and accurately later. Notably,
people experience a strong rush of emotions, such as nervous, shocked,
surprised, etc., which is often lacking when making ordinary choices. Not only do
people remember emotional experiences better, those very emotions can
subsequently alter the decisions that they make, either rationally or irrationally. In
a 2016 study, subjects participating in tasks that engaged positive emotions
showed less tendency in retrieving prior experiences and memories; and in
general made overconfident judgements (Treffers and Fehse 2016). It may not
seem as obvious but the so-called mundane choices we make every day are also
emotionally driven. People tend to stick to choices that have given them positive
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experiences in the past and avoid selecting risky choices associated with
negative memory. Therefore, emotion is considered as a crucial component of
the intricate network of decision-making.
As discussed above, most of the decisions we make are guided by
emotion, either consciously or unconsciously. In his recent work, The Disordered
Mind, neuroscientist Eric Kandel used a simple model to describe emotions with
two axes that represent valence and intensity (Kandel 2018: 179). Valence is the
value of emotion that determines behavioral outcomes and intensity is the
strength of the emotion. This simplistic model is adequate to portray the
complexity of emotion as a continuous spectrum. As people make decisions,
contextual and environmental stimuli are perceived and interpreted. Stimuli are
often categorized as either positive or negative, which can induce positive or
negative reinforcements. The ability to precisely differentiate and evaluate
different stimuli for appropriate responses is crucial and often seems trivial for
healthy individuals. However, those with affective disorders, such as posttraumatic stress disorder (PTSD) or anxiety disorders, find it immensely difficult
to match their emotions to various stimuli from their surroundings. A fMRI study
on psychopathic inmates showed a correlation between their deficient paralimbic
system, including many structures responsible for emotional processing, and
their impaired moral judgements (Kiehl and Hoffman 2011). Specifically,
investigators detected increased activation in the amygdala, a structure in the
limbic system responsible for assigning emotional values to sensory stimuli, of
psychopathic inmates compared to non-psychopathic inmates during moral
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reasoning tasks. Interestingly, these psychopaths showed greatly reduced
activity in the amygdala but increased activity in the lateral frontal cortex, a region
involved in cognitive functions, during an affective memory task (Kiehl and
Hoffman 2011). A typical relationship between stimulus and valence would be
how positive input elicits appetitive or approaching behavior, whereas negative
input induces aversive or avoidance behavior. For example, an animal would
normally approach a positive stimulus such as food but avoid a negative stimulus
such as a predator. However, depending on the contextual cues or other
convergent stimuli, this basic relationship may differ. For instance, the animal
would choose to suppress its fear towards its imminent threat and would risk its
life in protecting its offspring from predators. As we discussed earlier, these
decisions are often made instantaneously. However, the exact mechanism
through which individuals precisely distinguish and evaluate opposing stimuli
during emotional decision-making remains elusive.
This study investigated the anatomical framework of the modulatory
mechanism of opposing valences in response to various stimuli as part of the
emotional decision-making circuitry. By understanding this mechanism better, we
can offer further insight into differences in the regulatory models between normal
and disordered minds, especially mood disorders with decision-making deficits.

B) The Role of The Amygdala in Emotional Decision-Making:
Decision-making deficits have been reported in individuals who have
suffered from neuropsychiatric disorders such as addiction, pathological
gambling, Parkinson’s disease (PD), etc. (Bechara 2001; Kobayakawa et al.
3

2010). Previous studies on decision-making have been using the Iowa Gambling
Task (IGT) as a standard tool to assess participants’ abilities in making choices.
The major requirements in IGT that ensure its assimilation to real-life decisionmaking are the uncertainty of outcomes and the variability in rewards and
punishments (Gupta et al. 2011).Participants choose multiple cards, one by one,
from four decks of cards. Each selection comes with monetary rewards and
punishments. The four decks are split into advantageous and disadvantageous
decks. By using this tool, several studies indicated that multiple neural structures
are involved in different aspects of decision-making, particularly the ventromedial
prefrontal cortex (VMPC) and the amygdala (Bechara et al. 1994; Bechara et al.
1999; Bechara et al. 2000; Bechara et al. 2003). Compared to control subjects,
patients with bilateral amygdalae damages as well as those with bilateral VMPC
damages preferred the disadvantageous decks (immediate, large rewards but
delayed, larger punishments), which eventually yield an overall loss (Bechara et
al. 1999; Bechara et al. 2003). Similar results were also observed in substance
abusers, pathological gamblers, PD patients, bipolar disorder patients, etc.
(Bechara and Damasio 2002; Kobayakawa et al. 2008; Yechiam et al. 2008;
Kobayakawa et al. 2010). Participants with dysfunctional amygdalae also showed
a void in skin conductance responses (SCRs), a measure of reactivity of emotion
that is normally generated in healthy individuals before and after picking a deck.
In other words, these individuals fail to showcase the ability to integrate distinct
emotional responses to opposing valences (the emotional aspects associated
with winning and losing). Another example of the involvement of the amygdala in
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decision-making is demonstrated in Parkinson’s disease. PD patients also
perform poorly on IGT tests with a preferential bias towards disadvantageous or
risky selections (Kobayakawa et al. 2008; Kobayakawa et al. 2010). Kobayakawa
and colleagues postulated that the tendency towards risky choices by PD
patients is the consequence of emotional impairment from amygdala damage
(Kobayakawa et al. 2010). Diminished emotional responses to both reward and
punishment in PD patients were illustrated by lower SCRs and impaired
recognition of facial expression of certain emotions (Kan et al. 2002;
Sprengelmeyer et al. 2003; Suzuki et al. 2006; Kobayakawa et al. 2008).
Emotional apathy associated with a dysfunctional limbic system involving the
amygdala has also been observed in PD (Braak et al. 1994; Braak et al. 1996;
Harding et al. 2002; Saito et al. 2003).
The amygdala, also referred to as the amygdaloid complex, is an almondshaped structure that is morphologically and functionally organized into roughly
13 nuclei; of which the basolateral portion of the amygdala (BL) contains the
largest cells of the complex (Krettek and Price 1978; Sah et al. 2003). The
amygdala is considered as the “orchestrator” of emotion. The crucial role of the
amygdala, specifically the BL, in orchestrating different emotional states by
bridging the unconscious and conscious aspects of emotion is in large part due
to its dense internuclear and intranuclear connections (Sah et al. 2003). To put it
simply, as the BL receives sensory information from all modalities, it decodes
and assigns emotional significance to those inputs. From there, it relays the
decoded signals onward to different structures responsible for the conscious and
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unconscious aspects of emotion. The unconscious route refers to the autonomic
responses such as increasing heart rate, sweating, jumping, etc.; while the
conscious part refers to the “feeling state” or essentially, the emotional state (Sah
et al. 2003; Kandel 2018). According to the James-Lange theory of emotion, our
bodily physiological response is the driving force of the conscious or emotional
state (James 1884). Therefore, we feel because we react; or we’re scared
because we run. The BL is comprised of the lateral (LA), basolateral (BLA), and
the basomedial (BMA) nuclei (Krettek and Price 1978). The LA receives the
majority of the sensory inputs to the amygdala (McDonald 1998; LeDoux 2003).
Classical fear conditioning studies have demonstrated that the auditory
conditioned stimuli (CS) that can induce fear response travel from the auditory
thalamus directly to the amygdala and indirectly via the auditory cortex first
before reaching the LA (Mascagni et al. 1993; Romanski and LeDoux 1993;
McDonald 1998; LeDoux 2003). The direct thalamo-amygdala pathway is
relatively quicker but not as precise as the indirect thalamo-cortico-amygdala
pathway (Kandel 2018: 183). This explains why people react to loud noise
instantly before registering the source of the noise. Morphologically, three
neuronal classes have been identified in the LA and BLA: the predominant Class
I of large, spiny, and pyramidal shaped neurons; Class II neurons, comprises
~5% of recorded neurons, are spine-sparse with smaller, ovoid cell bodies;
several small, spherical neurons were classified as Class III (McDonald
1982).Class I neurons, also known as pyramidal or projection neurons (PNs), are
further segregated into the anterior and posterior subdivisions of BLA based on
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their perikaryal size. Magnocellular PNs, with relatively larger cell bodies,
predominate the anterior portion of the BLA (BLAa) and parvocellular PNs, with
relatively smaller cell bodies, populate the posterior portion (BLAp) (Krettek and
Price 1978; McDonald 1982; Sah et al. 2003). Similarly, LA is also divided into
larger-celled dorsolateral, smaller-celled ventrolateral, and intermediate
subdivisions (Sah et al. 2003).
D
Bregma -1.755 mm Bregma -1.855 mm

Bregma -2.355 mm

L

M
V

Bregma -1.055 mm

BLAa
BLAp
BMAp
BMAp

BLAa

BMAp

Figure 1.1 Color-coded Maps of the Distribution of
Parvo- and Magno-cellular PNs in BLA. Magnocellular
PNs (cyan) and parvocellular PNs (blue) from anterior to
posterior BLA. Images of coronal sections obtained from the
Allen Mouse Brain Atlas (2004). Available from:
https://mouse.brain-map.org/static/atlas
Since amygdalae involvement in both appetitive and aversive behaviors
has been established, recent studies have focused on investigating the
determining factors that distinguish PNs in the BLA that are driving opposing
valences (such as reward versus avoidance behaviors) (Namburi et al. 2015;
Beyeler et al. 2016; Correia and Goosens 2016; Kim et al. 2016; Beyeler et al.
2018). One group suggested that the specificity of the valence encoded by BLA
PNs is determined by their projection targets (Namburi et al. 2015; Beyeler et al.
2016; Beyeler et al. 2018). They reported that BLA PNs projecting to the nucleus
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accumbens (NAc) and central amygdala (CeA) show, respectively, preferential
responses to reward and aversion predictive cues (Beyeler et al. 2016).
Topographically, they could not detect a gradient of neurons responsive to
positive versus negative cues across the AP axis of the BLA. However, they were
able to record a preferential coding bias along the DV axis with stronger
responses to the positive cues recorded from BLA compared to LA (Beyeler et al.
2018). Another group, however, found that an anatomical and genetic
segregation between BLA PNs corresponded to positive and negative valences
(positive and negative neurons) (Kim et al. 2016). They identified two distinct
genetic markers, Rspo2 (R-spondin2) and Ppp1r1b (protein phosphatase 1
regulatory inhibitor subunit 1B), exclusively expressed on negative and positive
neurons, respectively. These genetically distinct and valence-specific neurons
are also spatially segregated with an AP gradient across the BLA. Rspo2+
neurons overlap with magnocellular PNs in the BLAa while Ppp1r1b+ neurons
correspond to parvocellular PNs in the BLAp. Interestingly, a recent study
identified a neural ensemble within the amygdala that encodes the
unpleasantness of pain and found these nociceptive neurons expressed the
negative valence marker Rspo2 but not the positive valence marker Ppp1r1b
(Corder et al. 2019).

C) Cholinergic Signaling in The Amygdala:
Since there is a dense cholinergic presence in the amygdala, it is of
interest to study the role of this neuromodulator in modulating the opposing
valence-encoding PNs in the BLA. Acetylcholine (ACh) is well-known in the
8
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Figure 1.2 Graphs from Previous Reports on the Distribution
of Valence-specific PNs in BLA. a: AP distribution of Rspo2+
and Ppp1r1b+ PNs (Kim et al., 2018). b, c: Graphs from Corder et
al., 2019 showing the distribution of nociceptive neurons from
anterior to posterior BLA (c) with majority of them are PNs
(Camk2a+) and express negative valence marker (Rspo2+) (d)

peripheral system as a primary excitatory neurotransmitter. However, its
functional role in the central nervous system (CNS) is more complex. Unlike its
counterpart in the periphery, central ACh is well-established as a
neuromodulator. Some of its modulatory effects include alternating neuronal
excitability, mediating neurotransmitter release, determining the fate of certain
neuronal ensembles, etc. (Wonnacott 1997; Rice and Cragg 2004; Zhang and
Sulzer 2004; Kawai et al. 2007). The cholinergic system contributes to the
regulation of cognitive tasks such as attention, learning, and memory
consolidation (Gold 2003; Power et al. 2003; Robinson et al. 2011). In fact,
studies have shown correlation between cognitive impairment and cholinergic
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system deficits. For instance, cholinergic cell loss is reported in Alzheimer’s
disease (Whitehouse et al. 1982; McGeer et al. 1984). Deficient ACh synthesis
and a dysfunctional cholinergic system in aged and demented CNS were
reported (Bartus et al. 1982). Similar cognitive dysfunctions were also observed
in young subjects when their cholinergic systems were artificially disturbed
(Bartus and Johnson 1976). Picciotto and colleagues reported in their 2012
review that the differential effects of cholinergic signaling on opposing behavioral
responses are modulated by receptor subtypes, their density, the population of
target, and the brain regions (Picciotto et al. 2012). BLA is densely innervated by
cholinergic fibers from the basal forebrain with PNs as the major target of
cholinergic innervation in BLA (Muller et al. 2011). Cholinergic signaling in BLA is
essential for emotion-related cognitive tasks such as fear learning and
consolidation of emotional memory (McGaugh 2004). Therefore, in order to
elucidate the modulatory effect of ACh on the opposing stimuli-driven BLA PNs, it
is imperative to look at the distribution pattern of cholinergic receptors relative to
the positive-negative neurons.
The mechanism of ACh release is mediated by two classes of cholinergic
receptors: the metabotropic muscarinic receptors (mAChRs) and the ionotropic
nicotinic receptors (nAChRs). A 1982 review by Bartus and colleagues
summarized results from previous studies on rodents and humans indicate an
age-related reduction in muscarinic receptor density (Bartus et al. 1982).
Similarly, a decrease in muscarinic receptors was reported in schizophrenic
patients in several post-mortem studies (Crook et al. 2000; Dean et al. 2002;
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Scarr et al. 2007). The mAChRs, belonged to the G-protein-coupled family, are
further categorized into 5 different subtypes: Gq (M1, M3, M5), and Gi (M2, M4).
Buckley et al. (1988) employed in situ hybridization techniques to investigate the
distribution of m1-m4 mRNAs across the rat CNS. They demonstrated that m1
receptor (M1R) mRNAs predominate the BLA compared to other subtypes
(Buckley et al. 1988). To compensate for the differences in mRNA’s translation
efficiency, other studies also looked at the protein expression of M1Rs and found
similar results (Levey et al. 1991; McDonald and Mascagni 2010). Specifically, in
the same study from 2010, McDonald and Mascagni further investigated the
neuronal localization of M1Rs and found majority of M1 immunoreactivity in the
cell bodies and proximal dendrite of BLA PNs. They also discovered an
anatomical distribution of M1 across BLA and LA. The anterior subdivisions of
both BLA and LA expressed the most “robust” M1 labeling (McDonald and
Mascagni 2010). Altogether, these studies suggest an anatomical distribution of
M1Rs across the BLA. This study offers further insight into this distribution in
relation to BLA PNs that encode positive and negative valences.

D) Objective, Hypothesis, and Aims:
The objective of this study was to investigate the differential expression of
M1 mAChR and vesicular ACh transporter (vAChT), a marker for cholinergic
terminals, between magnocellular and parvocellular BLA PNs as well as between
PL- and IL- projectors. These results can help portray an anatomical framework
of the cholinergic modulation of BLA PNs that drive opposing behavioral
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responses and to determine whether there is a preferential bias of this
modulation based on their projection targets. Based on the 2010 report by
McDonald and Mascagni on a topographical difference of M1R along the AP
axis, we hypothesize that magnocellular and parvocellular PNs that are distinctly
associated to anterior and posterior subdivisions of BLA also express a robust
difference on M1R. We also hypothesize that PL projectors, which were
prominently found in BLAa, express higher M1 intensity than IL projectors, which
were more equally distributed between BLA subnuclei. To test these hypotheses,
the following aims were proposed and accomplished:
Aim 1: Determine the differential expression of vAChT intensity across
different BLA subnuclei.
Aim 2: Determine the differential expression of M1Rs intensity across different
BLA subnuclei.
Aim 3: Determine the differential expression of M1Rs intensity between PLand IL- projectors.
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CHAPTER II: EXPERIMENTAL PROCEDURES
A) Tissue preparation and immunohistochemistry:
All animal handling and surgical procedures were conducted in accordance
with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Use and Care Committee
(IACUC) of the University of South Carolina. Three male and three female
C57BL/6J mice (8-12 weeks, Jackson Laboratory, Bar Harbor, ME) were
anesthetized with isoflurane and intracardially perfused with ice-cold 0.1M
phosphate buffered saline (PBS, pH 7.4) containing 0.5% sodium nitrite followed
by ice-cold 4% paraformaldehyde (PFA) in 0.4M phosphate buffer (PB, pH 7.4).
Brains were immediately extracted and postfixed overnight in 4% PFA in PB
(0.4M, pH7.4) at 4oC. 50 µm thick horizontal sections were collected using a
Vibratome (Leica Microsystems). Sections were stored in 0.1M PBS (pH 7.4) at
4oC until further processing. Three sections from each animal were later obtained
for vAChT labeling and 3 adjacent sections were used for M1R labeling.
Horizontal sections labeled and imaged were divided across the dorsoventral
(DV) axis of the BLA with the approximate Bregma as -4.44 mm (dorsal BLA), 4.56 mm (intermediate BLA), and -4.72 mm (ventral BLA), according to the
Mouse Brain in Stereotaxic Coordinates (Franklin and Paxinos 2013)
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Tissue sections were washed 3 times, 30 min total, in 0.05M tris-buffered
saline solution (TBS pH 7.6). Sections were blocked with TBS containing 10%
normal goat serum (NGS) and permeabilized with 0.5% Triton-X100 for 30 min.
Sections were then washed with TBS (0.05M pH7.6) for 5 min 3 times. Sections
were incubated overnight at room temperature with appropriate primary
antibodies (see Table A.3 for the list of antibodies) in 0.5% Triton and 2% NGS.
The following day, sections were thoroughly washed with 0.05M TBS 3 times, 10
min per wash. Sections were then incubated for 3 hours, covered from light, with
an appropriate secondary antibody conjugated with Alexa Fluor (Table A.3 for
details on antibodies and concentrations) in 0.5% Triton and 2% NGS. Sections
were washed for 10 minutes 2 times in TBS (0.05M pH 7.6) followed by
incubation in Nissl Red staining solution for 20 min. Sections were washed for 5
min 3 times in 0.05M TBS and then 5 min 2 times in 0.05M tris-buffered solution
(TB pH7.4), mounted on 0.5% gelatinized slides, and coverslipped with Prolong
Diamond Antifade Mountant (Invitrogen, Thermo Fisher). All slides were kept in
4oC until imaging.
B) Retrograde tracing study:
Mice were housed in temperature-controlled cages (with maximum of 5 mice
per cage) and maintained on a 12-hour light/dark cycle with ad libitum food and
water. Stereotaxic injections were conducted on adult wild-type male mice (n=5)
aged 8 – 12 weeks (C57BL/6J, Jackson Laboratory). All surgical procedures
were performed under aseptic conditions using a stereotaxic instrument
(Stoelting, IL). Mice were first anesthetized in an enclosed container with
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gaseous isoflurane (5%) and kept under anesthesia (2% isoflurane) using the
stereotaxic frame for the entire surgery. Mice were then unilaterally injected to PL
(AP: 1.9 mm, ML: -0.4 mm, DV: -2.0 → -1.9 mm) and IL (AP: 2.6 mm, ML: -0.4
mm, DV: -2.8 → -2.7 mm) with Cholera toxin subunit B conjugated with Alexa
Fluor 647 or 555 (CtB 647 and CtB 555), respectively (see Table A.3 for details
and concentrations). Ten days after injection, animals were perfused as indicated
above. 50 µm thick coronal sections were obtained with a Leica vibratome and
kept in 0.1M PBS at 4oC for later immunohistochemical processing. Sections
containing PL and IL were saved for validation of the injections. Four sections
from each animal containing BLA were selected and divided to anterior (AP 1.055mm), intermediate (AP -1.755 mm), posterior (AP -1.855 mm), and super
posterior (AP -2.355 mm), approximate Bregma from Allen Mouse Brain Atlas
(2004). Sections were subsequently processed for M1R labeling following the
procedure above but without Nissl Red staining. All sections from the same
animal were processed in the same well and sections from all 3 animals were
processed at the same time.
To demonstrate the dense cholinergic innervation from the basal forebrain to
the BLA but not CeA, an image of BLA from our anterograde tracing study was
also obtained (Figure A.1). Briefly, mice were stereotaxically injected to the basal
forebrain with AAV serotype 5 virus expressing GFP under the control of CAG
promoter (AAV5-CAG-GFP). Five weeks after injection, 50 µm coronal sections
containing BLA were stained with Nissl and imaged (Figure A.1).
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C) Image acquisition and data analysis:
All images of PL and IL injection sites were collected using the Invitrogen
EVOS FL Auto 2.0 Imaging system (Thermo Fisher Scientific Inc., USA). Ten
sections from each animal (n=5, male) containing PL and IL were imaged to
verify the specificity and the spread of the injections. Tiled images were acquired
at 4X objective using the Texas Red and Cy5 light cubes. The center of each
injection as well as its spread was determined with reference to the mouse brain
atlas (Franklin and Paxinos 2013). Only mice with the centers of injections
contained within PL and IL were selected for further processing and analysis
(Figure 2.1, n=3, male).
a.CtB 555

CtB 647

b.

Bregma 1.94 mm

PL
IL
Amygdala

Figure 2.1 Stereotaxic Injection Location and Validation
a: Schematic diagram of injections to PL and IL with CtB
647 (magenta) and CtB 555 (green), respectively. b: Light
microscopic image showing the center of injection at
Bregma 1.94 mm with its corresponding atlas image on the
left. Atlas images obtained from Paxinos and Franklin
(2004).
All sections with BLA were imaged using a Leica SP8 Multiphoton Confocal
System (Leica Microsystem Inc., IL, USA). The scope settings for all confocal
imaging remained the same throughout vAChT as well as M1 image collection
(see Table A.2 for details).
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All cell counts and fluorescent intensity measurements were done on Fiji
ImageJ 1.52i (National Institutes of Health, USA). The borders between
subnuclei were determined on the Nissl channel with reference to the Franklin
and Paxinos’ The Mouse Brain in Stereotaxic Coordinates (Franklin and Paxinos
2013). All images for intensity measurement were converted to 8-bit greyscale.
For antero-posterior quantification of vAChT-ir and M1R-ir, evenly spaced,
rectangular region-of-interest (ROIs) were generated using the Startup Macros
plugins in ImageJ (Figure 2.2a). The Polygon Selection Tool was used to outline
the BLA. The intersections of the BLA ROI and the rectangular ROIs were
generated and added to the ROI manager (Figure 2.2b). The average pixel
intensity for each of these ROIs were measured and a mouse brain atlas was
used to associate the approximate Bregma to the appropriate ROIs (Franklin and
Paxinos 2013) (Figure 2.2c).
ROIs of PL- and IL-projectors were outlined using the Oval Selection Tool on
ImageJ (Figure 2.3). A total of 2,795 projectors were counted (n=3, male). The
BLA and its subnuclei were outlined with the Polygon Selection Tool. The
average pixel intensity of M1R on PL- and IL-projectors were measured using
their respective ROIs on the 8-bit greyscale image of the M1R channel (Figure
2.3).
All pixel intensity values were background subtracted before any statistical
tests. The average pixel intensity of CeA was set as background. To determine
the significant difference between the two means, F-test was first performed to
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test the variances of the populations. Student’s t-test was then carried out (with
either equal or unequal variances according to the results from the F-test).
a.

b.

c.

Figure 2.2 ROIs for Antero-posterior Quantification
a: Rectangular ROIs generated with Startup Macros
plugins in ImageJ and BLA ROI outlined with Polygon
selections Tool. b: Intersections of rectangular ROIs
and BLA ROIs combined. c: Selected ROIs with their
associated Bregma (numbers in cyan)

LA

BLAa

BMA
p
BLAv

Figure 2.3 ROIs for PL
and IL projectors PLprojectors (magenta), IL
projectors (green), and
dual projectors (yellow)
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CHAPTER III: RESULTS
A) Differential Distribution of Cholinergic Innervation:
To elucidate the role of ACh in modulating BLA PNs that are driving
antagonistic behaviors, we first examined the differential cholinergic inputs
relative to these valence-specific PNs. Not only do these PNs express exclusive
genetic markers, they are morphologically distinct with larger-celled
magnocellular PNs and smaller-celled parvocellular PNs corresponding to
appetitive and aversive behavioral responses, respectively (Kim et al. 2016).
Using antibodies to the vesicular acetylcholine transporter (vAChT) to label
cholinergic axon terminals, we observed a significant difference in vAChT
immunoreactivity (vAChT-ir) surrounding magnocellular versus parvocellular PNs
(Figure 3.1 b-d). Specifically, a prominent presence of vAChT+ axons was
observed around magnocellular neurons in BLAa whereas a markedly lower
density of vAChT+ axons was observed around parvocellular neurons in BLAp
(Figures 3.1 and 3.2). No vAChT+ cell bodies were observed in this study. The
morphologies of these parvocellular and magnocellular PNs are consistent with
those described in an EM study on rat amygdala by McDonald (McDonald 1982).
Both cell types show pyramidal-like cell body (Figure 3.2). Quantification on the
morphological properties also produced a difference between the soma diameter
of these two groups of PNs. Cell bodies of magnocellular PNs are 19-20 µm long
and 13-14 µm wide, while cell bodies of parvocellular PNs are 15-16 µm long and
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10-11 µm wide (Table A.1). In the transition between BLAa and BLAp, both cell
types were found intermingled and surrounded by moderate vAChT labeling
(Figure 3.2 g-i).

a.

c.

BLAa

d.
BLAp

b.

Figure 3.1 vAChT Immunofluorescence. a: Tiled image of a
horizontal BLA showing vAChT-ir (magenta), approximate Bregma 4.56 mm (intermediate section). vAChT density is significantly higher
in BLAa compared to that in BLAp and LaVL. b, c, d: Images of
vAChT-ir from BLAa (c), BLAp (d), and at the transition between
BLAa and BLAp (b). Cell-body labeled with Nissl stain (cyan). Scale
bars: 25 µm (b-d),150 µm (a). z-series: 21.89 µm (a), 5.4 µm (b-d).
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a.

d.

g.

b.

e.

h.

c.

f.

i.

Figure 3.2 vAChT-ir Associated with Parvocellular and Magnocellular PNs.
Images showing different density levels of vAChT+ axon terminals in BLAa (ac), BLAp (d-f), and in the transition between the two subnuclei (g-i).
Magnocellular PNs appear with larger cell bodies (b) compared to parvocellular
cells (e). A mixture of both cell types can be seen at the transition (h). Scale
bars: 25 µm. z-series: 5.4 µm.
A differential distribution of cholinergic inputs between BLA subnuclei was
observed using immunoperoxidase technique in a previous report by Muller and
colleagues (Muller et al. 2011). Specifically, it was reported that BLAa and BLAp
seemed to receive the densest innervation compared to LA, CeA, and BMP.
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Based on this assertion, along with our observation on a significant difference in
vAChT-ir surrounding PNs in BLAa and BLAp, we quantified and compared the
difference in vAChT fluorescent intensity levels along the anterior-to-posterior
axis of BLA with approximate Bregma ranged from -0.5 mm to -2.75 mm (Figure
3.3 d-f). This antero-posterior quantification was also examined separately along
the DV axis by arbitrarily splitting BLA into 3 groups: dorsal, intermediate, and
ventral sections with approximate Bregma of -4.44mm, -4.56 mm, and -4.72 mm,
respectively (Figure 3.3) (Franklin and Paxinos 2013). Regarding Muller et al.
observation on a low density of vAChT+ axon terminals in central nucleus, we
also observed a void of cholinergic fiber in CeA in our anterograde tracing data
investigating cholinergic innervation from basal forebrain to different amygdalar
subnuclei (Figure A.1). Therefore, we decided to normalize BLA vAChT intensity
to CeA vAChT intensity. The intensity of vAChT fluorescent labeling is highest in
the anterior region (between Bregma -0.75 mm and -1.25 mm) and substantially
decreases moving caudally toward BLAp. This distribution pattern remains
consistent throughout the BLA along the DV axis with no apparent sex difference.
Almost a 12- to 13-fold difference was measured between the highest intensity
around Bregma -1.25 mm and the lowest intensity around Bregma -2.5 mm in the
dorsal and intermediate groups (Figure 3.3 a-b). This difference is not as
significant in the ventral group (about 3-fold) (Figure 3.3c). Total vAChT-ir levels
between BLA subnuclei were also measured and compared (Figure 3.4). As
expected, BLAa expressed significantly higher vAChT intensity compared to
other subnuclei (p<0.05). This is consistent across dorsal, intermediate, and
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a.

A
M

b.

DV -4.44 mm

c.

DV -4.56 mm

DV -4.72 mm

L
CeC

P

BLAa

BLAa

BLAa
CeC
CeL

CeL
CeM

LaVL

BLAp

BLAp

BLAp
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Figure 3.3 Antero-posterior Quantification of vAChT-ir. a-c: Representative images of vAChT-ir at
dorsal (a), intermediate (b), and ventral (c) levels of BLA (approximate Bregma levels from Paxinos
and Franklin 2013. Scale bars 150 µm. d-f: graphs showing the differential levels of vAChT
fluorescent intensity from anterior to posterior BLA at dorsal (d), intermediate (e), and ventral (f)
levels. Results show mean ± SEM (n=6, 3 male and 3 female).

ventral BLA with no apparent sex difference (Figure 3.4). Similar to our rostrocaudal quantification above, the difference in this labeling intensity between
BLAa and BLAp also reduces in the ventral BLA. Since we only normalized within
each group but not between groups, we try to avoid inter-group comparison.
However, our observations from the labeling from all 6 animals combined with
the values seems to suggest that the overall vAChT fluorescent intensity is
higher in dorsal and intermediate BLAa relative to that in ventral BLAp. On the
other hand, vAChT-ir in BLAp, although still significantly lower compared to
BLAa, seems to increase going from dorsal to ventral BLA. Altogether, our data
suggest a preferential bias of cholinergic inputs to magnocellular PNs in BLAa,
especially to the dorsal and anterior two-thirds of the BLAa.
a.
***

**

60
40
20
0

80

Fluorescent
Intensity

80

Fluorescent
Intensity

80

Fluorescent
Intensity

c.

b.

60
40
20
0

LaVL

BLAa

BLAp

*

60
40
20
0

LaVL

BLAa

BLAp

LaVL

BLAa

BLAp

Figure 3.4 Average vAChT Fluorescent Intensity between Different
Amygdalar Subnuclei. a-c: Bar graphs showing average vAChT fluorescent
intensity in BLAa, BLAp and LaVL from dorsal (a), intermediate (b), and
ventral (c) BLA. Results show mean ± SEM (n=6, 3 male and 3 female).
***P<0.00001, **P<0.0001, *P<0.0001
B) Differential Distribution of M1 Muscarinic Receptors:
Since a marked difference in the density of vAChT+ axon terminals
surrounding magnocellular and parvocellular PNs has been established, we also
examined the expression of M1 receptors relative to these populations.
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Interestingly, we also observed a difference in the distribution pattern of M1R-ir
between these PNs (Figure 3.5 and 3.6). Strong perikaryal staining was
observed in the majority of magnocellular PNs. Only a few parvocellular PNs
show cell body labeling, all of which were less intense. Perikaryal staining was
seen in the cytoplasm but not in the nucleus of PNs which is consistent with
previous reports (McDonald and Mascagni 2010). Dense punctate neuropilar
staining was observed surrounding both cell types with those surrounding
magno- cells appearing to be more dense (Figure 3.6). A 2013 EM study by
Muller and colleagues identified neuropilar labeling as mostly from dendritic
shafts and spines, as well as many axon terminals (Muller et al. 2013). Somata
diameters between these two population were also quantified and displayed
consistent results with previous reports (Table A.1)
Following the establishment of a spatial bias of cholinergic inputs to different
amygdalar subnuclei, we examined the distribution pattern of M1R between
these subnuclei. McDonald and Mascagni previously reported, in an
immunohistochemistry study on rat, a variation in immunoreactivity levels of M1
receptors between different nuclei of the amygdala with the most robust labeling
in the anterior two-thirds of the BLA (McDonald and Mascagni 2010). Based on
this assertion, together with our observation above on the differential levels of
M1R-ir between magno- and parvo- cells, we performed similar antero-posterior
quantification as in our vAChT study. Similar distribution patterns across dorsal,
intermediate, and ventral regions of BLA were observed (Figure 3.7).
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c.

a.

BLAa

d.
BLAp

b.

Figure 3.5 M1R Immunofluorescence. a: Tiled image of a horizontal
BLA sho M1R-ir (red) at Bregma level -4.56 mm (intermediate section).
b, c, d: Images of M1R-ir from BLAa (c) and BLAp (b,d). Strong
perikaryal labeling in magnocellular PNs in BLAa (c). Cell body labeled
with Nissl stain (grey). Scale bars: 25 µm (b-d), 150 µm (a). z-series:
21.89 µm (a), 4.97 µm (b-d).
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a.

d.

g.

b.

e.

h.

c.

f.

i.

Figure 3.6 M1R-ir Relative to Parvocellular and Magnocellular PNs. a:
Images depict differential expression of M1R in BLAa (a-c), BLap (d-i).
Morphologies of magnocellular (b) and parvocellular (e, h) PNs are
consistent with those observed from our vAChT study. Strong perikaryal
staining can be observed in the cytoplasm and proximal dendrites of
magnocellular PNs (c). Very light soma labeling can be observed in a few
parvocellular PNs (f). The neuropilar labeling surrounding magnocellular
PNs (c) seems to be more dense than that surrounding parvocellular PNs (f,
i). Scale bars: 25 µm. z-series: 5.4 µm
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Consistently, the highest intensity was measured approximately around Bregma 1.50 mm to -1.75 mm. M1R-ir intensity seems to remain consistently high moving
rostrally from Bregma -1.75 mm up to -1.00 mm in intermediate and ventral
regions, but a 30% drop was measured in the dorsal sections. The most rostral
region (Bregma -0.5 to -0.75 mm) expressed the lowest level of M1. Overall, the
caudal two-thirds of BLAa seem to express the highest M1R intensity followed by
the rostral part of BLAa and BLAp, both of which seem to express M1R-ir
equally. Interestingly, this AP distribution of M1R, especially from male animals,
resembles the AP distribution of nociceptive neurons in BLA previously reported
by Corder et al. (2019) (Figure 3.7 and 3.8). We observed a slight different
pattern in female mice which is more of a bell shape. Average M1R-ir in BLA
subnuclei were also determined. Along the DV axis, the highest average M1R
intensity was measured in BLAa and the lowest was measured in BLAp.
However, the intensity difference between BLAa and BLAp was only significant in
the dorsal sections (Figure 3.9).
C) Differential Expression of M1R between PL- and IL- Projectors:
It was suggested that PNs in BLAa and BLAp project to PL and IL,
respectively (Kim et al. 2016). Since we have seen a significant difference in
M1R expression between these BLA subnuclei, a similar pattern of expression
should be observed between PL and IL projectors in BLA. We first determined
the topographical distribution of PL- and IL- projectors along the AP axis of BLA.
A total of 2,795 CtB+ projectors were counted from 3 male mice, which is
approximately 932 cells per animal. On average, 838 IL projectors and 297 PL
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Figure 3.7 Antero-posterior Quantification of M1R-ir. a-c: Representative images of M1R-ir
at dorsal (a), intermediate (b), and ventral (c) levels of BLA (approximate Bregma levels from
Paxinos and Franklin 2013). Scale bars 150 µm. d-f: graphs showing the differential levels of
M1R fluorescent intensity from anterior to posterior BLA at dorsal (d), intermediate (e), and
ventral (f) levels. Results show mean ± SEM (n=6, 3 male and 3 female).
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Figure 3.8 Male versus Female Difference in Antero-posterior Distribution of M1R-ir. The difference in the
distribution patterns of M1R fluorescent intensity along the AP axis (Bregma -0.5 to -2.75 mm) from female (a-c)
versus male (d-f). Results show mean ± SEM (a-c: n=3, female; d-f: n=3, male)
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Figure 3.9 Average M1R Fluorescent Intensity between BLA Subnuclei.
a-c: Bar graphs showing average M1R fluorescent intensity in LA, BLAa, and
BLAp from dorsal (a), intermediate (b), and ventral (c) BLA. Intensity
measured in BLAa is significantly higher than that in BLAp in dorsal sections.
Results show mean ± SEM (n=6, 3 male and 3 female). *P<0.05
projectors were recorded with 203 of those (68.5% of PL-projectors and 24.5% of
IL-projectors) beign dual projectors that project to both IL and PL. From this
point, IL- and PL- projectors referred to those that solely project to IL or PL and
not including dual projectors. Topographically, most of the PL projecting neurons
clustered in the anterior region of BLA (Bregma -1.055 mm to -1.755 mm), while
IL projecting neurons dispersed throughout, spanning from the lateral part of
intermediate BLA to the posterior portion of BLA (Bregma -1.755mm to -2.355
mm) (Figures 3.10 a-d, A.3). This distribution was quantified along the AP axis,
regardless of BLA subnuclei. 53% of PL projectors (49 out of 93 cells) were
found in the intermediate BLA (Bregma -1.755 mm), which contains a major
portion of BLAa. Only 8% of PL-projectors were found in the posterior region of
BLA (Bregma -2.255 to -2.355 mm), which consists of a small caudal part of
BLAa and a large portion of BLAp. The remaining PL-projectors were equally
distributed between anterior and posterior regions (~20% each). IL-projectors
were evenly distributed (20-30% each) to intermediate, posterior, and superposterior BLA. We then determined the soma labeling of M1R on PL- and IL-
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projectors along this AP distribution (Figure 3.10 g). Since we disregard the
subnuclei, it seems that both projector populations express a similar level of
M1R-ir while PL-projectors express a slightly higher intensity than IL-projectors
throughout. Both projector populations expressed the highest intensity in the
rostral BLA (Bregma -1.255 mm) and the lowest intensity in the most caudal
region (Bregma -2.255 mm) with a 3- to 4- fold difference.
We also looked at the distribution of PL- and IL-projectors between BLA
subnuclei (Figure 3.11). The majority of PL-projectors (69%) were located in
BLAa. IL-projectors, however, did not project any topographical bias between
subnuclei. Interestingly, when we measured the M1R-ir intensity of each
projector population and compared them between subnuclei, substantial
differences were observed. Overall, both PL- and IL- projectors in LA and BLAa
expressed significantly higher M1R intensity than those in BLAp, BMAp, and
BLAv (p<0.001). We also looked at the AP segregation of PL- and IL-projectors
within BLAa and BLAp (Figure 3.12). Within BLAa, 75% of PL-projectors were
found between Bregma -1.255 and -1.755 mm, where the brightest M1R intensity
were measured. When we measured the M1R intensity between PL- and ILprojectors within the same subnuclei (either BLAa or BLAp), no significant
difference was detected. However, significant differences were measured when
we compared them between subnuclei, even within the same projector
population (Figure 3.13 b). Overall, the average M1R intensity in PL projectors is
significantly higher than M1R intensity in IL projectors.
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Figure 3.10 Antero-posterior Distribution of PL- and IL- projectors and of their Perikaryal M1R Labeling. a-d:
Images of coronal sections of BLA at anterior (a), intermediate (b), posterior (c), and super-posterior levels (d). Images
showing M1R-ir (red), PL projectors (magenta), and IL projectors (green). Scale bars: 150 µm. e,f: AP distribution of
PL- and IL- projectors (regardless of subnuclei). g: M1R intensity on PL- and IL- projectors along the AP axis. Results
show mean ± SEM (n=3, male).
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Figure 3.11 Distribution of PL- and IL-projectors and their Relative M1Rir between BLA subnuclei. a: Average M1R fluorescent intensity between
BLA subnuclei. M1R intensity in BLAa is significantly higher than that in BLAp
(p<0.05). b: Distribution of PL-and IL- projectors (%) in different subnuclei. c:
M1R intensity of PL- and IL- projectors in different subnuclei. PL- and ILprojectors in BLAa express significantly higher levels of M1R-ir fluorescent
intensity than those in BLAp (p<0.001). Results show mean ± SEM (n=3,
male).
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Figure 3.12 AP Distribution of PL- and IL-projectors in BLAa and BLAp
and their M1R-ir. a,c: AP distribution of PL- and IL-projectors (%) within
BLAa (a) and BLAp (c). b,d: Average M1R fluorescent intensity of PL- and ILprojectors with their approximate location along the AP axis within BLAa (b)
and BLAp (d). Results show mean ± SEM (n=3, male)
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Figure 3.13 Differential Expression of M1R between PLand IL- Projectors and between Subnuclei. a: Differential
expression of M1R between PL and IL projectors (magenta
and green, respectively (*p<0.001). b: Differential
expression of M1R between PL-projectors in BLAa and
those in BLAp (magenta, *p<0.001)); as well as between ILprojectors in BLAa and those in BLAp (green, *p<0.01).
Results show mean ± SEM (n=3, male).
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CHAPTER IV:DISCUSSION
A previous EM study by Muller and colleagues reported that dendritic
shafts and spines of PNs in BLAa are the main targets of cholinergic inputs from
the basal forebrain (Muller et al. 2011). Physiological properties of BLA PNs are
also altered by cholinergic transmission. Together, these studies suggested that
PNs’ functions in BLAa are largely modulated by cholinergic signaling. Valencespecific PNs in BLA are not only spatially segregated, but they also express
distinct morphological properties and genetic markers. We wanted to determine
whether these distinct BLA PNs differentially express cholinergic markers.
Topographically, we have established a differential distribution of cholinergic
innervation between BLA subnuclei as well as between these two groups of PNs.
Specifically, magnocellular PNs are surrounded by dense cholinergic terminals,
whereas parvocellular PNs receive significantly less innervation. The moderate
labeling captured at the transition between BLAa and BLAp, where a mixture of
both cell types was observed, seems to further implicate magnocellular PNs as
the main target of cholinergic inputs. Since magnocellular and parvocellular PNs
define the architecture of BLA to BLAa and BLAp, we also quantified the labeling
intensity of different BLA subnuclei. A substantial difference in vAChT labeling
intensity between BLAa and BLAp was measured. Unlike the observation by
Muller et al. (2011) from their light microscopic result about a dense vAChT-ir in
BLAp, we observed a very light labeling in BLAp, which is not much different from
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that in the ventrolateral LA (LaVL). This could be due to species differences or
the difference in sensitivity and specificity between antibodies and enzymes
employed by immunofluorescence versus immunoperoxidase techniques.
Interestingly, there seems to be a spatial segregation within BLAa and BLAp
subnuclei. Specifically, the rostral and dorsal two-thirds of BLAa seems to
express brighter vAChT intensity than its caudoventral counterpart. However, the
higher intensity observed in the ventral portion of BLAp compared to its dorsal
region could be due to it being transitioned to BMAp. Since BMAp is the
parvocellular subdivision of BMA, it is difficult to discern from the parvocellular
cells in BLAp. Together, our data suggest magnocellular PNs that drive negative
valences receives significantly higher levels of cholinergic inputs compared to
parvocellular PNs that drive positive valences.
As mentioned above, dendritic shafts and spines of PNs are the main
targets of cholinergic inputs to BLAa (Muller et al. 2011). The same group also
reported in their 2013 EM study that almost all dendritic shafts (90%), 60% of
dendritic spines, and many axon terminals in the BLAa were M1R+. Collectively,
these studies suggest a crucial role of M1R to the cholinergic effects onto PNs.
Similar to our vAChT study, we also examined the distribution of M1R across
BLA subnuclei and between parvocellular and magnocellular PNs. We found a
high portion of magnocellular cells in BLAa showing strong perikaryal staining,
specifically in the cell cytoplasm and proximal dendrite. The same EM study also
confirmed that these perikaryal M1R were associated with the endoplasmic
reticulum and Golgi apparatus, indicating that they are in the process of being
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transported to distal dendrites and spines. Interestingly, we could not observe
such strong staining in the soma of parvocellular PNs. One possibility is that
parvocellular PNs are more efficient at transporting proteins to their processes. If
that is the case, we should observe a higher neuropilar labeling in BLAp than that
in BLAa. However, it seems that neuropilar staining in BLAa is still relatively more
dense. Further analysis investigating the difference in neuropilar labeling as well
as the proportion of different M1R+ neuropilar structures between BLAa and
BLAp is needed.
We also quantified the fluorescent intensity of M1R along the AP axis and
between subnuclei. Opposite to our vAChT results, we found the ventrocaudal
portion of BLAa expressed the brightest M1R intensity. Our finding on the
marked resemblance between the AP distribution of M1R and the distribution of
nociceptive neurons (reported by Corder et al., 2019) suggests that M1R may be
preferentially expressed on a subset of negative neurons. It would be interesting
to see if this distribution pattern persists when we quantify perikaryal M1R-ir after
injection of colchicine, a substance that blocks the transportation of proteins from
a cell body to its processes. The higher M1R-ir intensity measured in the ventral
portion of BLAp, again, could be due to the transition between BLAp and BMAp.
Also, neuropilar structures from PNs in neighboring subnuclei such as BMAp or
BLAv could also contribute to this increase in intensity.
When we measured the M1R-ir fluorescence intensity between different
projector populations in BLA, we were able to show that the differential
expression of M1R between these PNs correlates to their topographical
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distribution. Specifically, PL projectors, whose AP distribution matched that of
M1R, expressed significantly higher M1R than IL projectors, which were more
evenly distributed. Another study in our lab looking at other projector populations
found similar results. Particularly, we found that CeM projectors, whose presence
is significantly higher in BLAp than BLAa (~5-fold difference), expressed
significantly lower M1R intensity than NAc projectors, whose distribution between
BLAa and BLAp is less skewed. Previous reports have shown that the
downstream projection target defines the specific valence of BLA PNs (Namburi
et al. 2015; Beyeler et al. 2016; Beyeler et al. 2018). However, studies on the
neural basis of this valence segregation suggested that this projection-based
idea is not sufficient (Kim et al. 2016). Particularly, although the first group
reported that NAc projectors in BLA are driven by positive stimuli, the latter group
pointed out that this could be due to a higher percentage of NAc projectors being
ppp1r1b+. It would be interesting to compare the expression of M1R between
Ppp1r1b+ and Rspo2+ NAc projectors. We were able to show that magnocellular
IL projectors in BLAa expressed significantly higher M1R expression than
parvocellular IL projectors in BLAp. This implicates that M1Rs are differentially
expressed on Rspo2+ and Ppp1r1b+ IL projectors. Future studies using specific
antibodies for Ppp1r1b and Rspo2 are suggested.
Several studies indicated that PNs in the BLA drive antagonistic
behavioral responses. Our data suggested a differential expression of cholinergic
markers between these opposing valence-encoding PNs in the BLA. Specifically,
we established a preferential bias of cholinergic inputs and receptors to
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magnocellular PNs in BLAa that correspond to negative valences.
Electrophysiological studies have shown that cholinergic inputs from the basal
forebrain (BF) result in biphasic responses in PNs of BLA. Specifically, photostimulation of cholinergic terminals originated from BF induced a large inhibitory
response followed by a slower, sustained M1R-mediated excitatory response in
BLA PNs (Aitta-aho et al. 2018). Interestingly, another study reported that the
effects of BF inputs on BLA PNs depend on their active state (Unal et al. 2015).
Specifically, BF cholinergic signaling excites active PNs and inhibits inactive PNs
in BLA, which can enhance the signal-to-noise ratio. The inhibitory effect exerted
by BF inputs on PNs at rest occurred through two phases. The first phase was
through a nicotinic-mediated activation of local GABAergic neurons, which
subsequently inhibit PNs. The second phase was via a direct activation of M1Rs
on PNs. The excitatory effect induced by BF inputs on active PNs was also
suggested to be M1R-mediated (Unal et al. 2015). The significant presence of
cholinergic markers in BLAa compared to their weak labeling in BLAp in our
study suggest that this signal-to-noise enhancement mechanism regulated by
ACh is more prevalent in negative PNs. It is possible that PL- and IL- projectors
residing in BLAa which are responsive to negative stimuli receive a more precise
modulatory mechanism by cholinergic signaling than their counterparts in BLAp
which are responsive to positive stimuli.
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APPENDIX A: SUPPLEMENTARY DATA AND FIGURES

a.

b.

CeA

CeA

Figure A.1 Innervation of Cholinergic Fibers from
the Basal Forebrain in BLA. Cholinergic fibers
(green, a) termination in BLA. No fibers were observed
in CeA. Cell bodies labeled with Nissl stain (cyan, b).
Scale bars: 150 µm
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a.

c.

b.

d.

Figure A.2 Antibody Specificity. Images of BLAa showing NAc
projectors (green) and M1R (red) with α-M1R antibody (c,d) and
without α-M1R antibody (a,b). Scale bars: 75 µm
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Figure A.3 PL- and IL-projectors Distribution Images of coronal sections showing the
distribution of IL projectors (a-d) and PL projectors (e-h) from anterior (a,e), intermediate (b,f),
posterior (c,g), and super-posterior (d,h) BLA. Scale bars: 150 µm. z-series: 21.89 µm

Table A.1 Soma diameters of magnocellular
and parvocellular PNs.
Soma Diameter (µm)
Cell Type

Length

Width

Magnocellular (n=17)

19.54 ± 0.35

13.42 ± 0.34

Parvocellular (n=16)

15.40 ± 0.17

10.98 ± 0.20

Table A.2 Microscope setting for Leica SP8.
Pinhole

Laser line - Intensity Gain

552 nm - 0.2503%
638 nm - 1.3%
488 nm - 1.3%
552 nm - 0.55%
488 nm - 1.3%
1 AU - 59.5
20X
552 nm - 0.35%
um
638 nm - 0.85%

63X 2 AU vAChT 200.6 um
63X 1.5 AU M1

Scan
speed

x (µm) y (µm)

z
(µm)

100 400 Hz 175.74 175.74 5.4
100 400 Hz 175.74 175.74 4.97
100
100 400 Hz 553.57 553.57 21.89
100

Table A.3 Antibodies and other products details.
Target
M1R
1o Ab

vAChT

2o Ab

Rabbit
Goat
Nissl
substance

Retrograde
Tracer

Antibody

Company

Concentration

Product
number

Rabbit anti-mAChRM1-Rb-Af340
goat anti-Vesicular
Acetylcholine
Transporter
Goat anti-rabbitAlexa Fluor 488
Donkey anti-goatAlexa Fluor 647
NeuroTraceTM
530/615 Red
Fluorescent Nissl
Stain
Cholera toxin B ,
Alexa FluorTM 555
conjugate (CtB 555)
Cholera toxin B,
Alexa FluorTM 647
conjugate (CtB 647)

Frontier
Institute Co., ltd

1:400

AB_2571791

Millipore

1:1,500

ABN100

Thermo Fisher

1:400

A21447

Thermo Fisher

1:400

A-11008

Invitrogen

1:100

N21482

Invitrogen

Invitrogen
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0.15 µL
(injection
volume)
0.15 µL
(injection
volume)

C34776

C34778

